<DOC>
	<DOCNO>NCT00513305</DOCNO>
	<brief_summary>The primary objective study determine whether low-dose cytarabine combination arsenic trioxide effective low-dose cytarabine alone achieve complete remission elderly patient ( â‰¥60 year age ) acute myeloid leukemia .</brief_summary>
	<brief_title>Cytarabine Combination With Arsenic Trioxide vs. Cytarabine Alone Elderly Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>The patient confirm acute myeloid leukemia ( AML ) . The patient unwilling unable tolerate conventional induction chemotherapy . The patient comorbid condition would limit life expectancy le 3 month . Patient must meet specific laboratory parameter study inclusion . The patient previous cytotoxic chemotherapy acute myeloid leukemia ( AML ) myelodysplastic syndrome ( MDS ) . Previous treatment lowdose cytarabine permit . The patient QT interval outside protocolspecified range . The patient laboratory value outside protocolspecified range . The patient concurrently treat cytotoxic therapy , radiation , investigational agent . The patient uncontrolled , severe cardiovascular pulmonary disease uncontrolled medical condition . The patient know central nervous system involvement AML .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>acute myeloid leukemia , cytarabine , arsenic trioxide .</keyword>
</DOC>